Positive results have been revealed from the first-in-human study transplanting an islet cell therapy into a patient with type 1 diabetes without the use of immunosuppression. The study was investigating Sana Biotechnology’s UP421, an allogeneic primary islet cell therapy that has been engineered with… Read More
New research by Australian biotechnology company Magellan Stem Cells has demonstrated potential therapeutic benefits of a stem cell therapy for osteoarthritis. The Phase I/II clinical trial assessed the safety and efficacy of MAG200, Magellan Stem Cells’ off-the-shelf allogeneic (donor) stem cell therapy for osteoarthritis of the… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been another busy week in the world of cell therapy, with the first… Read More
News round-up for 17-21 June by DDW Senior Digital Content Editor Diana Spencer. It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of… Read More
Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse. The ALPHA3 trial will… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The ongoing innovation and development in the drug discovery sector relies on a number… Read More
News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More
Allogene Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of ALLO-316, an AlloCAR T investigational product for the treatment of advanced or metastatic renal cell carcinoma (RCC). ALLO-316 targets CD70, which is highly expressed in… Read More
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Tr1X’s TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched haematopoietic stem cell transplantation (HSCT). The company plans to initiate a Phase I study of… Read More
Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). The study results were published in Cell Stem Cell, in a paper titled ‘Hypoimmune islets achieve insulin independence after allogeneic transplantation in a… Read More
Researchers in the US have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer. Furthermore, these cells, called human type 2 innate lymphoid cells (ILC2s), can be expanded outside of… Read More
Lineage Cell Therapeutics and Cancer Research UK have announced encouraging primary and secondary endpoint results from their clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated… Read More
The US Food and Drug Administration has approved CellTrans’ Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. Lantidra is approved for the treatment of adults with type 1 diabetes who are unable… Read More
The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. The ISCT 2023 Annual Meeting took place in Paris, France… Read More
Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. The deal also provides Eterna… Read More
LyGenesis and Imagine Pharma have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes. The research collaboration will use Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis’ allogeneic cell therapy platform to develop… Read More
